Core Viewpoint - Ironwood Pharmaceuticals (IRWD) and Bausch Health (BHC) are both active in the branded gastrointestinal (GI) drug market, focusing on treatments for irritable bowel syndrome (IBS) and other therapeutic areas. Ironwood is a smaller, focused company centered around its key GI drug, while Bausch Health is a larger, diversified drugmaker with a broader product range [1][2]. Group 1: Ironwood Pharmaceuticals (IRWD) - Ironwood's primary product, Linzess (linaclotide), is approved for treating IBS with constipation (IBS-C) and functional constipation, marketed in collaboration with AbbVie (ABBV) [3][4]. - In the first nine months of 2025, Ironwood's share of net profit from Linzess sales in the U.S. was $244.1 million, with sales increasing due to strong demand [5]. - Ironwood anticipates total revenues of $450-$475 million in 2026, representing a 54% year-over-year increase at the midpoint [6]. - The company is developing apraglutide, a next-generation GLP-2 analog for short bowel syndrome with intestinal failure, with a confirmatory study expected to start in the first half of 2026 [7]. - Despite the positive outlook for Linzess and apraglutide, Ironwood's heavy reliance on a single product raises concerns [8]. Group 2: Bausch Health (BHC) - Bausch Health operates across multiple therapeutic areas, with its eye health business under Bausch + Lomb Corporation, and reported fourth-quarter 2025 results that missed earnings estimates but exceeded revenue expectations [9]. - The Salix business segment, which includes GI products, is a significant revenue contributor, with Xifaxan being the top revenue generator [11]. - Bausch Health expects 2026 revenues to be between $10.625 billion and $10.875 billion, with $5.375 billion to $5.475 billion coming from Bausch + Lomb [10][14]. - The company faced a setback with the failure of the RED-C clinical program, which did not meet its primary endpoint [15]. - Bausch Health's high levels of debt and generic competition in the market are ongoing concerns [16]. Group 3: Comparative Analysis - The Zacks Consensus Estimate for Ironwood's 2026 sales suggests a year-over-year increase of approximately 50.5%, while Bausch Health's estimate indicates a 4.2% increase [17][19]. - In the past six months, Ironwood's shares have surged by 291.5%, contrasting with a 21% decline in Bausch Health's shares [22]. - Ironwood's shares trade at a price-to-sales (P/S) ratio of 2.42, significantly higher than Bausch Health's 0.22, indicating a more expensive valuation for Ironwood [23]. - Ironwood is rated as a Zacks Rank 1 (Strong Buy), while Bausch Health holds a Zacks Rank 3 (Hold), suggesting a more favorable investment outlook for Ironwood [26]. - Despite Bausch Health's diversified operations, Ironwood's growth momentum and potential for long-term profitability position it as the better investment choice [28].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]

Key Takeaways BHC shares fell after Q4 EPS missed estimates despite 9% revenue growth and a top-line beat.BHC's Salix and International units drove gains, with Xifaxan sales up 10% year over year.BHC guided 2026 revenues to $10.625-$10.875B, above consensus expectations.Bausch Health Companies Inc. (BHC) reported mixed results for the fourth quarter of 2025. Consequently, shares are trading down in after-hours trading.Adjusted earnings per share (EPS) of $1.08 missed the Zacks Consensus Estimate of $1.21 bu ...

Last October 2025, Bausch Health Companies Inc. ( BHC ) jumped by 1% after it posted third quarter results . This time, the fourth-quarter bottom line missed expectations. Both its revenue for Q4 and revenue guidance forChris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of underval ...

overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward- looking statements speak only as of the date hereof. The Company undertakes no ...

Core Insights - Bausch Health reported revenue of $2.8 billion for the quarter ended December 2025, reflecting a year-over-year increase of 9.3% and exceeding the Zacks Consensus Estimate of $2.7 billion by 3.38% [1] - The company's EPS was $1.08, down from $1.15 in the same quarter last year, resulting in an EPS surprise of -10.5% compared to the consensus estimate of $1.21 [1] Revenue Breakdown - Total Bausch + Lomb revenues reached $1.41 billion, surpassing the average estimate of $1.37 billion by analysts, marking a year-over-year increase of 9.8% [4] - Revenues from Diversified Products were $255 million, exceeding the estimated $233.84 million, with an 11.8% increase year-over-year [4] - Bausch + Lomb's Vision Care segment generated $778 million, closely matching the average estimate of $778.13 million, reflecting a 7.6% year-over-year growth [4] - Surgical revenues amounted to $249 million, above the average estimate of $239.46 million, indicating a 7.8% increase year-over-year [4] - Total revenues excluding Bausch + Lomb were $1.39 billion, exceeding the $1.33 billion estimate, with an 8.8% year-over-year growth [4] - International revenues were reported at $306 million, surpassing the average estimate of $280.41 million, representing a 9.7% year-over-year increase [4] - Solta Medical revenues were $137 million, slightly below the average estimate of $143.46 million, showing a year-over-year decline of 0.7% [4] - Salix revenues reached $693 million, exceeding the estimated $669.92 million, with a year-over-year increase of 9.3% [4] - Bausch + Lomb Pharmaceuticals generated $378 million, surpassing the average estimate of $353.78 million, reflecting a significant year-over-year growth of 16% [4] Stock Performance - Bausch shares have returned -11.8% over the past month, compared to a -1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

分组1 - Bausch Health reported quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.21 per share, and showing a decrease from $1.15 per share a year ago, resulting in an earnings surprise of -10.50% [1] - The company posted revenues of $2.8 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.38%, and an increase from $2.56 billion year-over-year [2] - Bausch has surpassed consensus revenue estimates three times over the last four quarters, while it has only surpassed consensus EPS estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 13.8% since the beginning of the year, compared to the S&P 500's zero return [3] - The current consensus EPS estimate for the coming quarter is $0.82 on revenues of $2.43 billion, and for the current fiscal year, it is $4.07 on revenues of $10.49 billion [7] - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the bottom 20% of the Zacks Industry Rank, indicating potential challenges for stock performance [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-14956 Bausch Health Companies Inc. (Exact Name of Registrant as Specified in its Charte ...

Bausch Health (NYSE:BHC) Q4 2025 Earnings call February 18, 2026 05:00 PM ET Company ParticipantsGaren Sarafian - VP and Head of Investor RelationsGlen Santangelo - Managing DirectorJJ Charhon - EVP and CFOJonathan Sadeh - CMO and Head of Research and DevelopmentLes Sulewski - VP of Spec Pharma and Biotech Equity ResearchThomas Appio - CEOUmer Raffat - Equity Research of Biotech, Pharma-major, and Specialty PharmaConference Call ParticipantsMichael Freeman - Equity Research AnalystNone - AnalystNone - Analy ...

Bausch Health (NYSE:BHC) Q4 2025 Earnings call February 18, 2026 05:00 PM ET Company ParticipantsGaren Sarafian - VP and Head of Investor RelationsGlen Santangelo - Managing DirectorJJ Charhon - EVP and CFOJonathan Sadeh - CMO and Head of Research and DevelopmentLes Sulewski - VP of Spec Pharma and Biotech Equity ResearchThomas Appio - CEOUmer Raffat - Equity Research of Biotech, Pharma-major, and Specialty PharmaConference Call ParticipantsMichael Freeman - Equity Research AnalystNone - AnalystNone - Analy ...